BIOMAT Database Logo BIOMAT Database Logo

Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage. 1998

D C Montefiori, and R G Collman, and T R Fouts, and J Y Zhou, and M Bilska, and J A Hoxie, and J P Moore, and D P Bolognesi
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA. monte005@mc.duke.edu

Human immunodeficiency virus type 1 (HIV-1) uses a variety of chemokine receptors as coreceptors for virus entry, and the ability of the virus to be neutralized by antibody may depend on which coreceptors are used. In particular, laboratory-adapted variants of the virus that use CXCR4 as a coreceptor are highly sensitive to neutralization by sera from HIV-1-infected individuals, whereas primary isolates that use CCR5 instead of, or in addition to, CXCR4 are neutralized poorly. To determine whether this dichotomy in neutralization sensitivity could be explained by differential coreceptor usage, virus neutralization by serum samples from HIV-1-infected individuals was assessed in MT-2 cells, which express CXCR4 but not CCR5, and in mitogen-stimulated human peripheral blood mononuclear cells (PBMC), where multiple coreceptors including CXCR4 and CCR5 are available for use. Our results showed that three of four primary isolates with a syncytium-inducing (SI) phenotype and that use CXCR4 and CCR5 were neutralized poorly in both MT-2 cells and PBMC. The fourth isolate, designated 89.6, was more sensitive to neutralization in MT-2 cells than in PBMC. We showed that the neutralization of 89.6 in PBMC was not improved when CCR5 was blocked by having RANTES, MIP-1alpha, and MIP-1beta in the culture medium, indicating that CCR5 usage was not responsible for the decreased sensitivity to neutralization in PBMC. Consistent with this finding, a laboratory-adapted strain of virus (IIIB) was significantly more sensitive to neutralization in CCR5-deficient PBMC (homozygous delta32-CCR5 allele) than were two of two SI primary isolates tested. The results indicate that the ability of HIV-1 to be neutralized by sera from infected individuals depends on factors other than coreceptor usage.

UI MeSH Term Description Entries
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D002461 Cell Line, Transformed Eukaryotic cell line obtained in a quiescent or stationary phase which undergoes conversion to a state of unregulated growth in culture, resembling an in vitro tumor. It occurs spontaneously or through interaction with viruses, oncogenes, radiation, or drugs/chemicals. Transformed Cell Line,Cell Lines, Transformed,Transformed Cell Lines
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015483 HIV Antibodies Antibodies reactive with HIV ANTIGENS. AIDS Antibodies,HIV-Associated Antibodies,HTLV-III Antibodies,HTLV-III-LAV Antibodies,LAV Antibodies,Lymphadenopathy-Associated Antibodies,T-Lymphotropic Virus Type III Antibodies, Human,HIV Associated Antibodies,HTLV III Antibodies,HTLV III LAV Antibodies,Lymphadenopathy Associated Antibodies,T Lymphotropic Virus Type III Antibodies, Human,Antibodies, AIDS,Antibodies, HIV,Antibodies, HIV Associated,Antibodies, HIV-Associated,Antibodies, HTLV III,Antibodies, HTLV-III,Antibodies, HTLV-III-LAV,Antibodies, LAV,Antibodies, Lymphadenopathy Associated,Antibodies, Lymphadenopathy-Associated
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D054405 Chemokine CCL3 A CC chemokine with specificity for CCR1 RECEPTORS and CCR5 RECEPTORS. It is a chemoattractant for NK CELLS; MONOCYTES; and a variety of other immune cells. This chemokine is encoded by multiple genes. CCL3 Chemokine,CCL3L1 Chemokine,CCL3L2 Chemokine,CCL3L3 Chemokine,Chemokine CCL3L1,Chemokine CCL3L2,Chemokine CCL3L3,BB-10010,Chemokine (C-C Motif) Ligand 3,Chemokine (C-C Motif) Ligand 3-Like 1,Chemokine (C-C Motif) Ligand 3-Like 2,LD78alpha Chemokine,LD78beta Chemokine,MIP-1alpha,Macrophage Inflammatory Protein 1-alpha,Small Inducible Cytokine A3,BB 10010,BB10010,CCL3, Chemokine,CCL3L1, Chemokine,CCL3L2, Chemokine,CCL3L3, Chemokine,Chemokine, CCL3,Chemokine, CCL3L1,Chemokine, CCL3L2,Chemokine, CCL3L3,Chemokine, LD78alpha,Chemokine, LD78beta,Macrophage Inflammatory Protein 1 alpha

Related Publications

D C Montefiori, and R G Collman, and T R Fouts, and J Y Zhou, and M Bilska, and J A Hoxie, and J P Moore, and D P Bolognesi
Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals.
January 2009, Journal of virology,
D C Montefiori, and R G Collman, and T R Fouts, and J Y Zhou, and M Bilska, and J A Hoxie, and J P Moore, and D P Bolognesi
Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage.
March 1998, Journal of virology,
D C Montefiori, and R G Collman, and T R Fouts, and J Y Zhou, and M Bilska, and J A Hoxie, and J P Moore, and D P Bolognesi
Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage.
September 1998, Journal of virology,
D C Montefiori, and R G Collman, and T R Fouts, and J Y Zhou, and M Bilska, and J A Hoxie, and J P Moore, and D P Bolognesi
Human immunodeficiency virus type 1 neutralization by plasma from B or F genotype infected individuals.
February 2005, Memorias do Instituto Oswaldo Cruz,
D C Montefiori, and R G Collman, and T R Fouts, and J Y Zhou, and M Bilska, and J A Hoxie, and J P Moore, and D P Bolognesi
Novel subtype C human immunodeficiency virus type 1 envelopes cloned directly from plasma: coreceptor usage and neutralization phenotypes.
September 2010, The Journal of general virology,
D C Montefiori, and R G Collman, and T R Fouts, and J Y Zhou, and M Bilska, and J A Hoxie, and J P Moore, and D P Bolognesi
Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity.
March 1998, Journal of virology,
D C Montefiori, and R G Collman, and T R Fouts, and J Y Zhou, and M Bilska, and J A Hoxie, and J P Moore, and D P Bolognesi
Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1.
November 1998, Journal of virology,
D C Montefiori, and R G Collman, and T R Fouts, and J Y Zhou, and M Bilska, and J A Hoxie, and J P Moore, and D P Bolognesi
Specificity of antibody-dependent cellular cytotoxicity in sera from human immunodeficiency virus type 2-infected individuals.
September 1993, AIDS research and human retroviruses,
D C Montefiori, and R G Collman, and T R Fouts, and J Y Zhou, and M Bilska, and J A Hoxie, and J P Moore, and D P Bolognesi
Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation.
December 2005, The Journal of general virology,
D C Montefiori, and R G Collman, and T R Fouts, and J Y Zhou, and M Bilska, and J A Hoxie, and J P Moore, and D P Bolognesi
Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off.
September 1997, Journal of virology,
Copied contents to your clipboard!